相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Sun Pharma Advanced Research Company (SPARC) has entered into a definitive asset purchase agreement to sell its rare pediatric disease priority review voucher for $195 million to an undisclosed buyer. - The voucher was granted by the FDA following approval of Sezaby, SPARC's medication indicated for the treatment of neonatal seizures. - SPARC CEO Anil Raghavan stated the sale will enable acceleration of pipeline asset development and strengthen the company's external innovation strategy. - The Priority Review Voucher program incentivizes development of treatments for rare pediatric diseases by allowing expedited review of future drug applications.
- Sun Pharma's experimental oral drug SCD-044 (Vibozilimod) failed to meet primary endpoints in Phase 2 trials for both psoriasis and atopic dermatitis, missing the 75% improvement target in PASI and EASI scores at 16 weeks. - The company has discontinued further clinical development of SCD-044, which was considered one of the more promising assets in SPARC's specialty pipeline for inflammatory disorders. - SPARC shares plunged 19% following the disappointing results, while Sun Pharma and its R&D arm will reassess the compound's future despite the drug being generally safe and well tolerated.
- SPARC experienced a significant 19% decline in share price following the failure of its psoriasis drug trial. - The clinical trial setback represents a major disappointment for the company's dermatology pipeline development. - The market reaction reflects investor concerns about the company's therapeutic prospects in autoimmune skin conditions.
- Sonidegib phosphate (Odomzo), currently approved for locally advanced basal cell carcinoma, is being investigated for multiple additional cancer indications including gastroesophageal junction adenocarcinoma and medulloblastoma. - The oral anticancer agent, developed by Sun Pharma Advanced Research (SPARC), has demonstrated potential in treating various solid tumors and hematologic malignancies, expanding its therapeutic scope. - The drug's development program spans across multiple challenging cancers, including glioblastoma, breast cancer, and chronic myelocytic leukemia, highlighting its potential as a versatile oncology treatment.
